Surveyed Rheumatologists Estimate That, in 2014, 24 Percent of Rheumatoid Arthritis Patients Who Receive Tofacitinib Would Be Biologic-Naive and 30 Percent Would Have Been Treated with at Least One TNF-alpha Inhibitor